Difference between revisions of "Part:BBa K5237010"

 
(72 intermediate revisions by 2 users not shown)
Line 38: Line 38:
 
<body>
 
<body>
 
     <!-- Part summary -->
 
     <!-- Part summary -->
     <section id="1">
+
     <section>
       <h1>Cathepsin B-Cleavable Linker (GFLG)</h1>
+
       <h1>Cathepsin B-Cleavable Linker: GFLG</h1>
       <p>This basic part encodes the GFLG linker, a cathepsin B-responsive cleavage site which could be used for targeted drug delivery or diagnostics in cancerous tissues. It was cloned into a mammalian expression vector with Gal4 and VP64 (link to BBa_K5237112). Functional testing in HEK293T cells showed that the GFLG linker was specifically cleaved in the presence of cathepsin B, while other linkers did not show this effect.</p>
+
       <p>This basic part encodes the GFLG peptide linker, a <b>cathepsin B-responsive cleavage site</b>, which can be used for targeted drug delivery or diagnostics in cancerous tissues. As a part of our PICasSO toolbox, the GFLG linker can facilitate precise control of protein activity through <b>cleavage-induced oligomerization of catalytically dead Cas proteins</b>. Through fluorescence readout assays, we verified that the overexpression of cathepsin B in cancer cells can potentially be leveraged for <b>novel therapeutic and biotechnological applications</b>.<br>
 +
We overexpressed cathepsin B in HEK293T cells to investigate the cleavage of five different peptide linkers using our mCherry Expression Cassette (<a href="https://parts.igem.org/Part:BBa_K5237022" target="_blank">BBa_K5237022</a>). To validate the functionality of the GFLG linker, we cloned it into a mammalian expression vector in between the Gal4 and VP64 domains (<a href="https://parts.igem.org/Part:BBa_K5237020" target="_blank">BBa_K5237020</a>). Functional testing of this fusion protein demonstrated efficient cleavage by cathepsin B <i>in vivo</i> when cells were treated with doxorubicin, while other tested linkers showed no significant response.
 +
</p>
 
       <p>&nbsp;</p>
 
       <p>&nbsp;</p>
    </section>
 
 
   <div id="toc" class="toc">
 
   <div id="toc" class="toc">
 
     <div id="toctitle">
 
     <div id="toctitle">
Line 49: Line 50:
 
     <ul>
 
     <ul>
 
       <li class="toclevel-1 tocsection-1"><a href="#1"><span class="tocnumber">1</span> <span class="toctext">Sequence
 
       <li class="toclevel-1 tocsection-1"><a href="#1"><span class="tocnumber">1</span> <span class="toctext">Sequence
             overview</span></a>
+
             Overview</span></a>
 
       </li>
 
       </li>
 
       <li class="toclevel-1 tocsection-2"><a href="#2"><span class="tocnumber">2</span> <span class="toctext">Usage and
 
       <li class="toclevel-1 tocsection-2"><a href="#2"><span class="tocnumber">2</span> <span class="toctext">Usage and
Line 55: Line 56:
 
       </li>
 
       </li>
 
       <li class="toclevel-1 tocsetction-3"><a href="#3"><span class="tocnumber">3</span> <span class="toctext">Assembly
 
       <li class="toclevel-1 tocsetction-3"><a href="#3"><span class="tocnumber">3</span> <span class="toctext">Assembly
             and part evolution</span></a>
+
             and Part Evolution</span></a>
 +
            <ul>
 +
              <li class="toclevel-2 tocsection-4"><a href="#3.1"><span class="tocnumber">3.1</span class="toctext"> Implementation of a Cleavage-Responsive Fluorescence Readout Assay</span></a>
 +
              </li>
 +
              <li class="toclevel-2 tocsection-5"><a href="#3.2"><span class="tocnumber">3.2</span class="toctext"> Changes to the Amino Acid Sequence of Cathepsin B Did Not Improve Cleavage Efficiency</span></a></li>
 +
              <li class="toclevel-2 tocsection-6"><a href="#3.3"><span class="tocnumber">3.3</span class="toctext"> Doxorubicin Induces Lysosomal Escape of Cathepsin B</span></a>
 +
              </li>
 +
            </ul>
 
       </li>
 
       </li>
       <li class="toclevel-1 tocsection-5"><a href="#4"><span class="tocnumber">4</span> <span
+
       <li class="toclevel-1 tocsection-7"><a href="#4"><span class="tocnumber">4</span> <span
 
             class="toctext">Results</span></a>
 
             class="toctext">Results</span></a>
 +
            <ul>
 +
              <li class="toclevel-2 tocsection-8"><a href="#4.1"><span class="tocnumber">4.1</span class="toctext"> The Peptide Linker GFLG Is Cleaved by Cathepsin B <i>in Vivo</i></span></a>
 +
              </li>
 +
              <li class="toclevel-2 tocsection-9"><a href="#4.2"><span class="tocnumber">4.2</span class="toctext"> mCherry and eGFP Can be Used as a Reporter System to Measure Cleavage Efficiency</span></a></li>
 +
              <li class="toclevel-2 tocsection-10"><a href="#4.3"><span class="tocnumber">4.3</span class="toctext"> Mature Cathepsin B Is Expressed in HEK293T Cells</span></a>
 +
              </li>
 +
            </ul>
 +
      </li>
 +
      <li class="toclevel-1 tocsetction-11"><a href="#5"><span class="tocnumber">5</span> <span class="toctext">Conclusion</span></a>
 +
            <ul>
 +
              <li class="toclevel-2 tocsection-12"><a href="#5.1"><span class="tocnumber">5.1</span class="toctext"> GFLG Is a Promising Candidate for Targeted Applications in Environments With Upregulated Cathepsin B Activity</span></a>
 +
              </li>
 +
              <li class="toclevel-2 tocsection-13"><a href="#5.2"><span class="tocnumber">5.2</span class="toctext"> Enabling the Functionalization of our PICasSO Toolbox Through Cathepsin B Cleavage</span></a>
 +
              </li>
 +
            </ul>
 
       </li>
 
       </li>
       <li class="toclevel-1 tocsection-8"><a href="#5"><span class="tocnumber">5</span> <span
+
       <li class="toclevel-1 tocsection-14"><a href="#6"><span class="tocnumber">6</span> <span
 
             class="toctext">References</span></a>
 
             class="toctext">References</span></a>
 
       </li>
 
       </li>
 
     </ul>
 
     </ul>
 
   </div>
 
   </div>
 +
</section>
  
 
   <section>
 
   <section>
Line 97: Line 121:
 
       parts crucial for testing every step of the cycle (design, build, test, learn) when engineering new parts
 
       parts crucial for testing every step of the cycle (design, build, test, learn) when engineering new parts
 
     </p>
 
     </p>
    <!-- Picture explaining parts collection -->
+
 
    <!-- below text not finished formatting-->
+
     <p>At its heart, the PICasSO part collection consists of three categories. <br><b>(i)</b> Our <b>DNA-binding proteins</b>
     <p>At its heart, the PICasSO parts collection consists of three categories. (i) Our <b>DNA-binding proteins</b>
+
 
       include our
 
       include our
 
       finalized enhancer hijacking Cas staple as well as half staples that can be used by scientists to compose entirely
 
       finalized enhancer hijacking Cas staple as well as half staples that can be used by scientists to compose entirely
 
       new Cas staples in the future. We also include our simple staples that serve as controls for successful stapling
 
       new Cas staples in the future. We also include our simple staples that serve as controls for successful stapling
       and can be further engineered to create alternative, simpler and more compact staples. (ii) As <b>functional
+
       and can be further engineered to create alternative, simpler and more compact staples. <br>
        elements</b>, we list additional parts that enhance the functionality of our Cas and Basic staples. These
+
      <b>(ii)</b> As <b>functional elements</b>, we list additional parts that enhance the functionality of our Cas and Basic staples. These
 
       consist of
 
       consist of
 
       protease-cleavable peptide linkers and inteins that allow condition-specific, dynamic stapling <i>in vivo</i>.
 
       protease-cleavable peptide linkers and inteins that allow condition-specific, dynamic stapling <i>in vivo</i>.
       Besides staple functionality, we also include the parts to enable the efficient delivery of PICasSO's with our
+
       Besides staple functionality, we also include the parts to enable the efficient delivery of PICasSO's constructs with our
       interkingdom conjugation system.
+
       interkingdom conjugation system. <br>
    </p>
+
      <b>(iii)</b> As the final component of our collection, we provide parts that support the use of our <b>custom readout
    <p>
+
      (iii) As the final component of our collection, we provide parts that support the use of our <b>custom readout
+
 
         systems</b>. These include components of our established FRET-based proximity assay system, enabling users to
 
         systems</b>. These include components of our established FRET-based proximity assay system, enabling users to
 
       confirm
 
       confirm
Line 121: Line 142:
 
       exceptional performance as described on our iGEM wiki and can serve as a reference. The other parts in the
 
       exceptional performance as described on our iGEM wiki and can serve as a reference. The other parts in the
 
       collection are versatile building blocks designed to provide future iGEMers with the flexibility to engineer their
 
       collection are versatile building blocks designed to provide future iGEMers with the flexibility to engineer their
       own custom Cas staples, enabling further optimization and innovation
+
       own custom Cas staples, enabling further optimization and innovation.<br>
 
     </p>
 
     </p>
 
     <p>
 
     <p>
Line 139: Line 160:
 
         <tr>
 
         <tr>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237001" target="_blank">BBa_K5237001</a></td>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237001" target="_blank">BBa_K5237001</a></td>
           <td>Half-Staple: dMbCas12a-Nucleoplasmin NLS</td>
+
           <td>Staple subunit: dMbCas12a-Nucleoplasmin NLS</td>
 
           <td>Staple subunit that can be combined to form a functional staple, for example with fgRNA and dCas9 </td>
 
           <td>Staple subunit that can be combined to form a functional staple, for example with fgRNA and dCas9 </td>
 
         </tr>
 
         </tr>
 
         <tr>
 
         <tr>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237002" target="_blank">BBa_K5237002</a></td>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237002" target="_blank">BBa_K5237002</a></td>
           <td>Half-Staple: SV40 NLS-dSpCas9-SV40 NLS</td>
+
           <td>Staple subunit: SV40 NLS-dSpCas9-SV40 NLS</td>
 
           <td>Staple subunit that can be combined to form a functional staple, for example with our fgRNA or dCas12a
 
           <td>Staple subunit that can be combined to form a functional staple, for example with our fgRNA or dCas12a
 
           </td>
 
           </td>
Line 156: Line 177:
 
         <tr>
 
         <tr>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237004" target="_blank">BBa_K5237004</a></td>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237004" target="_blank">BBa_K5237004</a></td>
           <td>Half-Staple: Oct1-DBD</td>
+
           <td>Staple subunit: Oct1-DBD</td>
 
           <td>Staple subunit that can be combined to form a functional staple, for example with TetR.<br>
 
           <td>Staple subunit that can be combined to form a functional staple, for example with TetR.<br>
 
             Can also be combined with a fluorescent protein as part of the FRET proximity assay</td>
 
             Can also be combined with a fluorescent protein as part of the FRET proximity assay</td>
Line 162: Line 183:
 
         <tr>
 
         <tr>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237005" target="_blank">BBa_K5237005</a></td>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237005" target="_blank">BBa_K5237005</a></td>
           <td>Half-Staple: TetR</td>
+
           <td>Staple subunit: TetR</td>
 
           <td>Staple subunit that can be combined to form a functional staple, for example with Oct1.<br>
 
           <td>Staple subunit that can be combined to form a functional staple, for example with Oct1.<br>
 
             Can also be combined with a fluorescent protein as part of the FRET proximity assay</td>
 
             Can also be combined with a fluorescent protein as part of the FRET proximity assay</td>
Line 168: Line 189:
 
         <tr>
 
         <tr>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237006" target="_blank">BBa_K5237006</a></td>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237006" target="_blank">BBa_K5237006</a></td>
           <td>Simple-Staple: TetR-Oct1</td>
+
           <td>Simple taple: TetR-Oct1</td>
 
           <td>Functional staple that can be used to bring two DNA strands in close proximity</td>
 
           <td>Functional staple that can be used to bring two DNA strands in close proximity</td>
 
         </tr>
 
         </tr>
 
         <tr>
 
         <tr>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237007" target="_blank">BBa_K5237007</a></td>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237007" target="_blank">BBa_K5237007</a></td>
           <td>Half-Staple: GCN4</td>
+
           <td>Staple subunit: GCN4</td>
 
           <td>Staple subunit that can be combined to form a functional staple, for example with rGCN4</td>
 
           <td>Staple subunit that can be combined to form a functional staple, for example with rGCN4</td>
 
         </tr>
 
         </tr>
 
         <tr>
 
         <tr>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237008" target="_blank">BBa_K5237008</a></td>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237008" target="_blank">BBa_K5237008</a></td>
           <td>Half-Staple: rGCN4</td>
+
           <td>Staple subunit: rGCN4</td>
 
           <td>Staple subunit that can be combined to form a functional staple, for example with rGCN4</td>
 
           <td>Staple subunit that can be combined to form a functional staple, for example with rGCN4</td>
 
         </tr>
 
         </tr>
 
         <tr>
 
         <tr>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237009" target="_blank">BBa_K5237009</a></td>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237009" target="_blank">BBa_K5237009</a></td>
           <td>Mini-Staple: bGCN4</td>
+
           <td>Mini staple: bGCN4</td>
 
           <td>
 
           <td>
 
             Assembled staple with minimal size that can be further engineered</td>
 
             Assembled staple with minimal size that can be further engineered</td>
Line 195: Line 216:
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237010" target="_blank">BBa_K5237010</a></td>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237010" target="_blank">BBa_K5237010</a></td>
 
           <td>Cathepsin B-Cleavable Linker (GFLG)</td>
 
           <td>Cathepsin B-Cleavable Linker (GFLG)</td>
           <td>Cathepsin B cleavable peptide linker, that can be used to combine two staple subunits ,to make responsive
+
           <td>Cathepsin B cleavable peptide linker, that can be used to combine two staple subunits, to make responsive
 
             staples</td>
 
             staples</td>
 
         </tr>
 
         </tr>
Line 204: Line 225:
 
         </tr>
 
         </tr>
 
         <tr>
 
         <tr>
           <td><a href="https://parts.igem.org/Part:BBa_K52370012" target="_blank">BBa_K5237012</a></td>
+
           <td><a href="https://parts.igem.org/Part:BBa_K5237012" target="_blank">BBa_K5237012</a></td>
 
           <td>Caged NpuN Intein</td>
 
           <td>Caged NpuN Intein</td>
 
           <td>Undergoes protein transsplicing after protease activation, can be used to create functionalized staple
 
           <td>Undergoes protein transsplicing after protease activation, can be used to create functionalized staple
Line 210: Line 231:
 
         </tr>
 
         </tr>
 
         <tr>
 
         <tr>
           <td><a href="https://parts.igem.org/Part:BBa_K52370013" target="_blank">BBa_K5237013</a></td>
+
           <td><a href="https://parts.igem.org/Part:BBa_K5237013" target="_blank">BBa_K5237013</a></td>
 
           <td>Caged NpuC Intein</td>
 
           <td>Caged NpuC Intein</td>
 
           <td>Undergoes protein transsplicing after protease activation, can be used to create functionalized staple
 
           <td>Undergoes protein transsplicing after protease activation, can be used to create functionalized staple
Line 216: Line 237:
 
         </tr>
 
         </tr>
 
         <tr>
 
         <tr>
           <td><a href="https://parts.igem.org/Part:BBa_K52370014" target="_blank">BBa_K5237014</a></td>
+
           <td><a href="https://parts.igem.org/Part:BBa_K5237014" target="_blank">BBa_K5237014</a></td>
 
           <td>fgRNA processing casette</td>
 
           <td>fgRNA processing casette</td>
 
           <td>Processing casette to produce multiple fgRNAs from one transcript, can be used for multiplexing</td>
 
           <td>Processing casette to produce multiple fgRNAs from one transcript, can be used for multiplexing</td>
 
         </tr>
 
         </tr>
 
         <tr>
 
         <tr>
           <td><a href="https://parts.igem.org/Part:BBa_K52370015" target="_blank">BBa_K5237015</a></td>
+
           <td><a href="https://parts.igem.org/Part:BBa_K5237015" target="_blank">BBa_K5237015</a></td>
 
           <td>Intimin anti-EGFR Nanobody</td>
 
           <td>Intimin anti-EGFR Nanobody</td>
 
           <td>Interkindom conjugation between bacteria and mammalian cells, as alternative delivery tool for large
 
           <td>Interkindom conjugation between bacteria and mammalian cells, as alternative delivery tool for large
Line 232: Line 253:
 
       <tbody>
 
       <tbody>
 
         <tr bgcolor="#FFD700">
 
         <tr bgcolor="#FFD700">
           <td><a href="https://parts.igem.org/Part:BBa_K52370016" target="_blank">BBa_K5237016</a></td>
+
           <td><a href="https://parts.igem.org/Part:BBa_K5237016" target="_blank">BBa_K5237016</a></td>
 
           <td>FRET-Donor: mNeonGreen-Oct1</td>
 
           <td>FRET-Donor: mNeonGreen-Oct1</td>
 
           <td>Donor part for the FRET assay binding the Oct1 binding cassette. Can be used to visualize DNA-DNA
 
           <td>Donor part for the FRET assay binding the Oct1 binding cassette. Can be used to visualize DNA-DNA
Line 270: Line 291:
 
         <tr>
 
         <tr>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237023" target="_blank">BBa_K5237023</a></td>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237023" target="_blank">BBa_K5237023</a></td>
           <td>Oct1 - UAS binding casette</td>
+
           <td>Oct1 - 5x UAS binding casette</td>
 
           <td>Oct1 and UAS binding cassette, that was used for the simulated enhancer hijacking assay.</td>
 
           <td>Oct1 and UAS binding cassette, that was used for the simulated enhancer hijacking assay.</td>
 
         </tr>
 
         </tr>
 
         <tr>
 
         <tr>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237024" target="_blank">BBa_K5237024</a></td>
 
           <td><a href="https://parts.igem.org/Part:BBa_K5237024" target="_blank">BBa_K5237024</a></td>
           <td>Minimal promoter Firefly luciferase</td>
+
           <td>TRE-minimal promoter- firefly luciferase</td>
 
           <td>Contains Firefly luciferase controlled by a minimal promoter. It was used as a luminescence readout for
 
           <td>Contains Firefly luciferase controlled by a minimal promoter. It was used as a luminescence readout for
 
             simulated enhancer hijacking.</td>
 
             simulated enhancer hijacking.</td>
Line 283: Line 304:
 
     </p>
 
     </p>
 
   </section>
 
   </section>
 +
 
   <section id="1">
 
   <section id="1">
     <h1>1. Sequence overview</h1>
+
     <h1>1. Sequence Overview</h1>
 
   </section>
 
   </section>
 
</body>
 
</body>
Line 297: Line 319:
  
 
<html>   
 
<html>   
 
 
    
 
    
 
<body>
 
<body>
  <section id="2">
+
<section id="2">
 
     <h1>2. Usage and Biology</h1>
 
     <h1>2. Usage and Biology</h1>
     <div class="thumb">
+
     <p>Cathepsin B is a cysteine protease that is significantly overexpressed in various cancer types, including breast and colorectal cancer (Ruan <i>et al.</i>, 2015). Proteolytic cleavage of pro-biologics, for example through cathepsin B activity, allows for precise temporal and spatial regulation of biopharmaceutical activity in therapeutic strategies (Bleuez <i>et al.</i>, 2022).<br>
      <div class="thumbinner" style="width:300px;"><a href="placeholder"
+
In this context, we introduce the cathepsin B-cleavable peptide linker GFLG as a functional addition to our PICasSO toolbox, enabling a wide range of therapeutic and synthetic biology applications. GFLG has been shown to be cleaved by cathepsin B (Wang <i>et al.</i>, 2024), with cleavage occurring either between the phenylalanine and leucine or after the second glycine of the linker (Rejmanová <i>et al.</i>, 1983; see <b>Fig. 2</b>).<br>
          class="image"><img alt="" src="https://static.igem.wiki/teams/5237/wetlab-results/gflg-cleavage1.svg" width="450"
+
Through a fluorescence readout assay in HEK293T cells, we identified GFLG as the most effective among five peptide linkers known to be cleaved by cathepsin B (Jin <i>et al.</i>, 2022; Shim <i>et al.</i>, 2022; Wang <i>et al.</i>, 2024). This linker could facilitate cleavage-induced oligomerization of Cas proteins via protein <i>trans</i>-splicing of caged intein fragments (<a href="https://parts.igem.org/Part:BBa_K5237012" target="_blank">BBa_K5237012</a>, <a href="https://parts.igem.org/Part:BBa_K5237013" target="_blank">BBa_K5237013</a>), further enhancing the capabilities of our system.<br>
             height="313" class="thumbimage"></a>
+
</p>
 +
 
 +
<div class="thumb" style="margin-top:12px;">
 +
  <div class="thumbinner" style="width:300px;">
 +
      <img alt="GFLG Peptide Linker Cleavage" src="https://static.igem.wiki/teams/5237/wetlab-results/gflg-cleavage2.svg" width="300" class="thumbimage">
 +
    <div class="thumbcaption">
 +
      <i><b>Figure 2: Cathepsin B Cleavage Sites in the GFLG Peptide Linker.</b></i>
 +
    </div>
 +
  </div>
 +
</div>
 +
</section>
 +
 
 +
  <section id="3">
 +
    <h1>3. Assembly and Part Evolution</h1>
 +
 
 +
<section id="3.1">
 +
<h3>3.1 Implementation of a Cleavage-Responsive Fluorescence Readout Assay</h3>
 +
    <p>We designed a fluorescence readout assay in HEK293T cells based on expression of mCherry induced by the <i>trans</i>-activator VP64. VP64 was conjugated to the DNA-binding domain (DBD) of Gal4 through the GFLG linker. We purchased the nucleotide sequence encoding the GFLG linker as an oligo. After annealing the oligo, we cloned it into a mammalian expression vector between the open reading frames for Gal4-DBD and VP64 via Golden Gate assembly (<a href="https://parts.igem.org/Part:BBa_K5237020" target="_blank">BBa_K5237020</a>). Binding of Gal4-DBD upstream of a gene encoding the fluorescence protein mCherry induces overexpression of mCherry by VP64. Consequently, separation of Gal4-DBD and VP64 by cathepsin B cleavage of the GFLG linker reduces mCherry expression (see <b>Fig. 3</b>).</p>
 +
 
 +
<div class="thumb" style="margin-top:15px;margin-bottom:18px;">
 +
  <div class="thumbinner" style="width:500px;"><img alt="Cathepsin B Fluorescence Readout Assay" src="https://static.igem.wiki/teams/5237/wetlab-results/catb-gal4-vp64-mechanism.svg" width="500"
 +
             class="thumbimage">
 
         <div class="thumbcaption">
 
         <div class="thumbcaption">
           <i><b>Figure 1</b></i><br>
+
           <i><b>Figure 3: Schematic Illustration of the Cathepsin B Fluorescence Readout Assay.</b></i> The DNA-binding domain (DBD) of Gal4 is conjugated to the transactivator domain VP64 via a cathepsin B-cleavable peptide linker. Binding of the Gal4-DBD to the upstream activating sequence (UAS) in proximity to the mCherry gene induces mCherry overexpression via VP64. Cathepsin B cleavage of the linker separates Gal4-DBD and VP64 and consequently reduces mCherry expression.
          <i>Lorem Ipsum</i>
+
 
         </div>
 
         </div>
 
       </div>
 
       </div>
 
     </div>
 
     </div>
    <p>Proteolytic cleavage of pro-biologics allows for the precise temporal and spatial regulation of biopharmaceutical activity in therapeutic applications (Bleuez <i>et al.</i>, 2022). Cathepsin B is a cysteine protease that is significantly overexpressed in different cancer types, including breast and colorectal cancer (Ruan <i>et al.</i>, 2015). Here, we introduce the cathepsin B-cleavable peptide linker GFLG enabling functionalization of our PICasSO system for various applications. GFLG has previously been reported to be cleaved by cathepsin B (Wang <i>et al.</i>, 2024). Cleavage either occurs between the phenylalanine and leucine or after the second glycine of the linker (see <b>Fig. 1</b>) (Rejmanová <i>et al.</i>, 1983). This linker can be used for the cleavage-induced oligomerization of Cas proteins through protein <i>trans</i>-splicing of caged intein fragments expanding the functionality of our PICasSO toolbox. We identified GFLG out of five peptide linkers previously reported to be cleaved by cathepsin B (Jin <i>et al.</i>, 2022; Shim <i>et al.</i>, 2022; Wang <i>et al.</i>, 2024) through a fluorescence readout system in HEK293T cells. <b>Figure 1: Cathepsin B Cleavage Sites in GFLG.</b></p>
+
 
  </section>
+
<p>We transfected our genetic constructs into HEK293T cells. The negative control was not transfected with the plasmid encoding cathepsin B. We investigated two different test conditions, in which we either transfected 30&nbsp;ng or 60&nbsp;ng of the plasmid encoding cathepsin B. The fluorescence intensity of mCherry was measured 48&nbsp;hours after transfection. Our initial tests did not result in the unambiguous identification of a cathepsin B-cleavable peptide linker (see <b>Fig. 4</b>). For all linkers, we did not observe a large decrease in fluorescence intensity between the negative control and test conditions. In some conditions, the fluorescence intensity even increased between the negative control and test conditions.</p>
  <section id="3">
+
 
    <h1>3. Assembly and part evolution</h1>
+
<div class="thumb" style="margin-top:15px;margin-bottom:15px;">
    <p>We designed a fluorescence readout assay in HEK293T cells based on expression of mCherry induced by the transactivator VP64. VP64 was conjugated to the DNA-binding domain (DBD) of Gal4 through the GFLG linker. We purchased the nucleotide sequence encoding the GFLG linker as an oligo. After annealing the oligo, we cloned it into a mammalian expression vector between the open reading frames for Gal4-DBD and VP64 via Golden Gate assembly (BBaK5237020). Binding of Gal4-DBD upstream of a gene encoding the fluorescence protein mCherry induces overexpression of mCherry by VP64. Consequently, separation of Gal4-DBD and VP64 by cathepsin B cleavage of the GFLG linker reduces mCherry expression (see <b>Fig. 2</b>). <b>Figure 2: Schematic Illustration of the Cathepsin B Fluorescence Readout Assay.</b> The DNA-binding domain (DBD) of Gal4 is conjugated to the transactivator domain VP64 via a cathepsin B-cleavable peptide linker. Binding of the Gal4-DBD to the upstream activating sequence (UAS) in proximity to the mCherry gene induces mCherry overexpression via VP64. Cathepsin B cleavage of the linker separates Gal4-DBD and VP64 and consequently reduces mCherry expression. We transfected our genetic constructs into HEK293T cells. The negative control was not transfected with the plasmid encoding cathepsin B. We investigated two different test conditions, in which we either transfected 30 ng or 60 ng of the plasmid encoding cathepsin B. The fluorescence intensity of mCherry was measured 48 hours after transfection. Our initial tests did not result in the unambiguous identification of a cathepsin B-cleavable peptide linker (see <b>Fig. 3</b>). For all linkers, we did not observe a large decrease in fluorescence intensity between the negative control and test conditions. In some conditions, the fluorescence intensity even increased between the negative control and test conditions. <b>Figure 3: Fluorescence Readout After 48 Hours for Five Different Peptide Linkers and Three Different Conditions.</b> The fluorescence intensity for mCherry was measured for five different linkers. The negative control was not transfected with the plasmid encoding cathepsin B. The fluorescence intensity of the negative control was set to one. Two different test conditions were investigated, in which either 30 ng or 60 ng of the plasmid encoding cathepsin B were transfected. Since cathepsin B is a lysosomal protease that is normally only active in the lysosome and the extracellular environment but not in the cytosol, we decided to change the native amino acid sequence of cathepsin B. Upon further investigation of the lysosomal maturation process of cathepsin B, we chose to express a truncated and mutated version of cathepsin B. We truncated the native cathepsin B amino acid sequence N-terminally by the first twenty amino acids. This N-terminally truncated version of cathepsin B lacks a signal peptide that normally facilitates translation of cathepsin B in the rough endoplasmic reticulum. Additionally, truncation of the first twenty amino acids of cathepsin B had previously been observed to maintain catalytic activity even in the absence of lysosomal proteases like pepsin (Müntener <i>et al.</i>, 2005). Additionally, we introduced three point mutations (D22A, H110A, R116A) in the amino acid sequence of cathepsin B. This has been shown to increase the activity of cathepsin B at higher pH values by disrupting the interactions of an occluding loop with the substrate binding pocket of cathepsin B (Nägler <i>et al.</i>, 1997). We performed the same fluorescence readout assay in HEK293T cells that we also used for wild-type cathepsin B. The fluorescence intensity of mCherry was measured 48 hours after transfection. However, we observed no decrease in fluorescence between our negative control and test conditions, indicating that Gal4-DBD-Linker-VP64 was not cleaved (see <b>Fig. 4</b>). Additionally, we performed a western blot, where the bands for the truncated and mutated version of cathepsin B were barely visible or absent altogether, indicating lower protein expression compared to the wild type (see <b>Fig. 7</b>). Another key insight from this experiment was that this version of cathepsin B was not activated by cleavage in the cell, as no additional protein bands were observed. <b>Figure 4: Fluorescence Readout for the Truncated and Mutated Version of Cathepsin B.</b> Since our truncated and mutated version of cathepsin B did not seem to be active in the cytosol, we decided to go back to wild-type cathepsin B. Therefore, we focused on improving the activity of wild-type cathepsin B in the cytosol. After consulting the literature, we decided to treat cells with the cytostaticum doxorubicin to induce lysosomal escape of cathepsin B, as had been previously reported (Bien <i>et al.</i>, 2004).</p>
+
  <div class="thumbinner" style="width:450px;"><img alt="Fluorescence Readout" src="https://static.igem.wiki/teams/5237/wetlab-results/catb-results/catb-fluorescent-readout-no-dox-w.svg" width="450"
 +
            class="thumbimage">
 +
        <div class="thumbcaption">
 +
          <i><b>Figure 4: Fluorescence Readout After 48&nbsp;Hours for Five Different Peptide Linkers and Three Different Conditions.</b></i> The fluorescence intensity for mCherry was measured for five different linkers. The negative control was not transfected with the plasmid encoding cathepsin B. The fluorescence intensity of the negative control was set to one. Two different test conditions were investigated, in which either 30&nbsp;ng or 60&nbsp;ng of the plasmid encoding cathepsin B were transfected.
 +
        </div>
 +
      </div>
 +
    </div>
 +
</section>
 +
 
 +
<section id="3.2">
 +
<h3>3.2 Changes to the Amino Acid Sequence of Cathepsin B Did Not Improve Cleavage Efficiency</h3>
 +
<p>Since cathepsin B is a lysosomal protease that is normally only active in the lysosome and the extracellular environment but not in the cytosol, we decided to change the native amino acid sequence of cathepsin B. Upon further investigation of the lysosomal maturation process of cathepsin B, we chose to express a truncated and mutated version of cathepsin B. We truncated the native cathepsin B amino acid sequence N-terminally by the first twenty amino acids. This N-terminally truncated version of cathepsin B lacks a signal peptide that normally facilitates translation of cathepsin B in the rough endoplasmic reticulum. Additionally, truncation of the first twenty amino acids of cathepsin B had previously been observed to maintain catalytic activity even in the absence of lysosomal proteases like pepsin (Müntener <i>et al.</i>, 2005). Additionally, we introduced three point mutations (D22A, H110A, R116A) in the amino acid sequence of cathepsin B. This has been shown to increase the activity of cathepsin B at higher pH values by disrupting the interactions of an occluding loop with the substrate binding pocket of cathepsin B (Nägler <i>et al.</i>, 1997).<br>
 +
We performed the same fluorescence readout assay in HEK293T cells that we also used for wild-type cathepsin B. The fluorescence intensity of mCherry was measured 48&nbsp;hours after transfection. However, we observed no decrease in fluorescence between our negative control and test conditions, indicating that Gal4-DBD-Linker-VP64 was not cleaved (see <b>Fig. 5</b>). Additionally, we performed a western blot, where the bands for the truncated and mutated version of cathepsin B were barely visible or absent altogether, indicating lower protein expression compared to the wild type (see <b>Fig. 9</b>). Another key insight from this experiment was that this version of cathepsin B was not activated by cleavage in the cell, as no additional protein bands were observed.</p>
 +
 
 +
<div class="thumb" style="margin-top:15px;margin-bottom:15px;">
 +
  <div class="thumbinner" style="width:450px;"><img alt="Fluorescence Readout" src="https://static.igem.wiki/teams/5237/wetlab-results/catb-results/catb-fluorescent-readout-mutated-and-truncated-w.svg" width="450"
 +
            class="thumbimage">
 +
        <div class="thumbcaption">
 +
          <i><b>Figure 5: Fluorescence Readout for the Truncated and Mutated Version of Cathepsin B.</b></i> Fluorescence intensity for mCherry was measured across five different linkers. The negative control, which was not transfected with the plasmid encoding cathepsin B, was assigned a fluorescence intensity value of one. Two test conditions were explored, where either 30 ng or 60 ng of the plasmid encoding cathepsin B was transfected.
 +
        </div>
 +
      </div>
 +
    </div>
 +
</section>
 +
 
 +
<section id="3.3">
 +
<h3>3.3 Doxorubicin Induces Lysosomal Escape of Cathepsin B</h3>
 +
<p>Since our truncated and mutated version of cathepsin B did not seem to be active in the cytosol, we decided to go back to wild-type cathepsin B. Therefore, we focused on improving the activity of wild-type cathepsin B in the cytosol. After consulting the literature, we decided to treat cells with the cytostaticum doxorubicin to induce lysosomal escape of cathepsin B, as had been previously reported (Bien <i>et al.</i>, 2004).</p>
 +
</section>
 +
 
 
   </section>
 
   </section>
 
   <section id="4">
 
   <section id="4">
 
     <h1>4. Results</h1>
 
     <h1>4. Results</h1>
     <p>The Peptide Linker GFLG Is Cleaved by Cathepsin B <i>in Vivo</i> We performed a fluorescence readout assay in HEK293T cells to investigate cathepsin B cleavage of different peptide linkers. 24 hours after transfection, we added doxorubicin in a final concentration of 500 nM to the cell supernatant. Figure 5 shows the fluorescence intensity of mCherry for five different peptide linkers (GFLG, FFRG, FRRL, VA, FK). The negative control was not transfected with the plasmid encoding cathepsin B. We investigated two different test conditions, in which we either transfected 30 ng or 60 ng of the plasmid encoding cathepsin B. The fluorescence intensity of mCherry was normalized by the measured fluorescence intensity of eGFP in each condition. Additionally, the values for 30 ng and 60 ng cathepsin B were normalized against the corresponding negative controls. One data point for the VA linker, transfected with 60 ng of the plasmid encoding cathepsin B, was excluded due to severe deviation from the other values. We conducted a two-way analysis of variance (ANOVA) to assess the significance of the observed differences between the negative control and the test conditions for each linker. As the negative control did not contain the plasmid encoding cathepsin B, we expected the measured fluorescence intensity of mCherry to be the highest in these conditions. However, this was only observed for the GFLG and FK linkers. Contrary to our expectations, the fluorescence intensity of the negative control was the lowest out of the three conditions tested for the remaining linkers. It appears that the addition of the plasmid encoding cathepsin B increases mCherry fluorescence intensity when the linker is not cleaved. However, this increase is only significant for the FFRG linker in the 60 ng condition. For the GFLG linker, we observed significant decreases in fluorescence intensity between the negative control and both test conditions, with no difference between the 30 ng and 60 ng conditions. For the FK linker, no significant decreases in fluorescence intensity between the negative control and the test conditions were observed. <b>Figure 5: Fluorescence Readout After 48 Hours for Five Different Peptide Linkers and Three Different Conditions.</b> The fluorescence intensity for mCherry was measured for five different linkers and normalized against a baseline eGFP fluorescence intensity. The negative control was not transfected with the plasmid encoding cathepsin B. The fluorescence intensity of the negative control was set to one. Two different test conditions were investigated, in which either 30 ng or 60 ng of the plasmid encoding cathepsin B were transfected. The fluorescent readout was analyzed using a two-way ANOVA. Medium: DMEM (10% FCS). P values: ns, P > 0.05; <b>, P < 0.05; </b><b>, P < 0.01; </b><b></b>, P < 0.001; <b></b><b></b>, P < 0.0001. mCherry and eGFP are Both Expressed in HEK293T Cells Figure 6 shows micrographs taken with a fluorescence microscope of three different conditions: the null control, the negative control and the test sample. All samples were transfected with plasmids encoding eGFP and mCherry. The null control and the negative control were not transfected with the plasmid encoding cathepsin B. The null control was also not transfected with any of the plasmids encoding Gal4-Linker-VP64 constructs. The test sample was transfected with 30 ng of the plasmid encoding cathepsin B and with the plasmid encoding Gal4-GFLG-VP64. As expected, the null control showed no detectable mCherry signal, since no plasmid encoding a Gal4-V64 construct was transfected. Consequently, mCherry overexpression via VP64 could not be induced. However, we observed a high fluorescence intensity for eGFP, indicating that the transfection was successful. The negative control showed strong signals of both mCherry and eGFP. Therefore, it can be assumed that the transfection was successful and that our mCherry readout system is functional. Interestingly, there are some cells which either seem to only express mCherry or eGFP and some cells that show no fluorescence signal. The test sample showed less eGFP and mCherry fluorescence compared to the negative control. We expected to observe reduced fluorescence intensity of mCherry, as the transfected cells would express cathepsin B, which cleaves the linker, thereby decreasing mCherry expression. <b>Figure 6: Micrographs of HEK293T Cells in Two Control Conditions and One Test Condition.</b> Micrographs were taken with a fluorescence microscope 48 hours after transfection. An overlay of brightfield, eGFP and mCherry is shown. The null control and the negative control were not transfected with the plasmid encoding cathepsin B. The Null Control was also not transfected with any of the plasmids encoding Gal4-Linker-VP64 constructs. The test sample was transfected with 30 ng of the plasmid encoding cathepsin B and with the plasmid encoding Gal4-GFLG-VP64. The micrograph of the test sample is not from the same biological replicate as the micrographs of the two controls. Mature Cathepsin B is Expressed in HEK293T Cells Figure 7 shows a western blot of the wild-type (wt) version of cathepsin B as well as the truncated and mutated version of cathepsin B (DELTA1-20, D22A, H110A, R116A). Cells of both cathepsin B versions were treated with 500 nM doxorubicin (dox) 24 hours post-transfection and incubated for additional 24 hours. For each condition, three replicates were blotted. We observed no differences in protein expression levels between the dox-treated and untreated wt versions of cathepsin B. For the truncated and mutated version of cathepsin B, however, only the untreated samples showed the corresponding band at approximately 36 kDa expected for this version of cathepsin B. Additionally, the bands of the truncated and mutated version appeared much weaker than the ones of the wt, indicating poorer protein expression. The household protein BETA-tubulin is visible in all samples at approximately 55 kDa. The wt cathepsin B additionally showed bands for pro-cathepsin B at approximately 42 kDa, a mature single-chain version of cathepsin B at approximately 33 kDa and a mature double-chain version at approximately 26 kDa. <b>Figure 7: Western Blot of Two Versions of Cathepsin B With and Without Doxorubicin.</b> From left to right: protein ladder, wild-type (wt) cathepsin B with (+) and without (-) doxorubicin, truncated and mutated version of cathepsin B with (+) and without (-) doxorubicin. The household protein, BETA-tubulin, is visible in all samples at 55 kDa. The wt cathepsin B also shows bands for pro-cathepsin B at 42 kDa, mature single-chain cathepsin B at 33 kDa and mature double-chain cathepsin B at 26 kDa. The band for the truncated and mutated version of cathepsin B can be seen in the samples without doxorubicin at 36 kDa. Discussion In conclusion, these findings demonstrate that our fluorescence-based readout assay can reliably detect cathepsin B-mediated cleavage of peptide linkers, with the GFLG linker showing particular susceptibility to cleavage. This makes GFLG a promising candidate for targeted applications in environments with upregulated cathepsin B activity, such as in cancerous tissues. Additionally, our cathepsin B-cleavage linker can be combined with caged inteins (Gramespacher <i>et al.</i>, 2017) conjugated to a dead Cas9 to selectively induce Cas-stapling in the presence of cathepsin B.</p>
+
     <section id="4.1">
  </section>
+
    <h3>4.1 The Peptide Linker GFLG Is Cleaved by Cathepsin B <i>in Vivo</i></h3>
   <section id="5">
+
<p>We performed a fluorescence readout assay in HEK293T cells to investigate cathepsin B cleavage of different peptide linkers. 24&nbsp;hours after transfection, we added doxorubicin in a final concentration of 500 nM to the cell supernatant. <b>Figure 6</b> shows the fluorescence intensity of mCherry for five different peptide linkers (GFLG, FFRG, FRRL, VA, FK). The negative control was not transfected with the plasmid encoding cathepsin B. We investigated two different test conditions, in which we either transfected 30&nbsp;ng or 60&nbsp;ng of the plasmid encoding cathepsin B. The fluorescence intensity of mCherry was normalized by the measured fluorescence intensity of eGFP in each condition. Additionally, the values for 30&nbsp;ng and 60&nbsp;ng cathepsin B were normalized against the corresponding negative controls. One data point for the VA linker, transfected with 60&nbsp;ng of the plasmid encoding cathepsin B, was excluded due to severe deviation from the other values. We conducted a two-way analysis of variance (ANOVA) to assess the significance of the observed differences between the negative control and the test conditions for each linker. As the negative control did not contain the plasmid encoding cathepsin B, we expected the measured fluorescence intensity of mCherry to be the highest in these conditions. However, this was only observed for the GFLG and FK linkers. Contrary to our expectations, the fluorescence intensity of the negative control was the lowest out of the three conditions tested for the remaining linkers. It appears that the addition of the plasmid encoding cathepsin B increases mCherry fluorescence intensity when the linker is not cleaved. However, this increase is only significant for the FFRG linker in the 60&nbsp;ng condition. For the GFLG linker, we observed significant decreases in fluorescence intensity between the negative control and both test conditions, with no difference between the 30&nbsp;ng and 60&nbsp;ng conditions. For the FK linker, no significant decreases in fluorescence intensity between the negative control and the test conditions were observed.</p>
     <h1>5. References</h1>
+
 
 +
<div class="thumb" style="margin-top:15px;margin-bottom:15px;">
 +
  <div class="thumbinner" style="width:450px;"><img alt="Fluorescence Readout" src="https://static.igem.wiki/teams/5237/wetlab-results/catb-results/catb-fluorescent-readout-final-results-w.svg" width="450"
 +
            class="thumbimage">
 +
        <div class="thumbcaption">
 +
          <i><b>Figure 6: Fluorescence Readout After 48&nbsp;Hours for Five Different Peptide Linkers and Three Different Conditions.</b></i> The fluorescence intensity for mCherry was measured for five different linkers and normalized against a baseline eGFP fluorescence intensity. The negative control was not transfected with the plasmid encoding cathepsin B. The fluorescence intensity of the negative control was set to one. Two different test conditions were investigated, in which either 30&nbsp;ng or 60&nbsp;ng of the plasmid encoding cathepsin B were transfected. The fluorescence readout was analyzed using a two-way ANOVA. Medium: DMEM (10% FCS). P values: ns, P > 0.05; *, P &le; 0.05; **, P &le; 0.01; ***, P &le; 0.001; ****, P &le; 0.0001.
 +
        </div>
 +
      </div>
 +
    </div>
 +
</section>
 +
 
 +
<section id="4.2">
 +
<h3>4.2 mCherry and eGFP Can be Used as a Reporter System to Measure Cleavage Efficiency</h3>
 +
<p><b>Figure 7</b> shows micrographs taken with a fluorescence microscope of three different conditions: the null control, the negative control and the test sample. <b>Figure 8</b> shows the corresponding graphs quantifying the fluorescence intensity in the different conditions. All samples were transfected with plasmids encoding eGFP and mCherry. The null control and the negative control were not transfected with the plasmid encoding cathepsin B. The null control was also not transfected with any of the plasmids encoding Gal4-Linker-VP64 constructs. The test sample was transfected with 30&nbsp;ng of the plasmid encoding cathepsin B and with the plasmid encoding Gal4-GFLG-VP64. As expected, the null control showed no detectable mCherry signal, since no plasmid encoding a Gal4-V64 construct was transfected. Consequently, mCherry overexpression via VP64 could not be induced. However, we observed a high fluorescence intensity for eGFP, indicating that the transfection was successful. The negative control showed strong signals of both mCherry and eGFP. Therefore, it can be assumed that the transfection was successful and that our mCherry readout system is functional. Interestingly, there are some cells which either seem to only express mCherry or eGFP and some cells that show no fluorescence signal. The test sample showed less eGFP and mCherry fluorescence compared to the negative control. We expected to observe reduced fluorescence intensity of mCherry, as the transfected cells would express cathepsin B, which cleaves the linker, thereby decreasing mCherry expression.</p>
 +
 
 +
<div class="thumb" style="margin-top:15px;margin-bottom:15px;">
 +
  <div class="thumbinner" style="width:800px;"><img alt="Fluorescence Readout" src="https://static.igem.wiki/teams/5237/wetlab-results/catb-fluorescence-microscope-w1.png" width="800"
 +
            class="thumbimage">
 +
        <div class="thumbcaption">
 +
          <i><b>Figure 7: Micrographs of HEK293T Cells in Two Control Conditions and One Test Condition.</b></i> Micrographs were taken with a fluorescence microscope 48&nbsp;hours after transfection. An overlay of brightfield, eGFP and mCherry is shown. The null control and the negative control were not transfected with the plasmid encoding cathepsin B. The Null Control was also not transfected with any of the plasmids encoding Gal4-Linker-VP64 constructs. The test sample was transfected with 30&nbsp;ng of the plasmid encoding cathepsin B and with the plasmid encoding Gal4-GFLG-VP64. The micrograph of the test sample is not from the same biological replicate as the micrographs of the two controls.
 +
        </div>
 +
      </div>
 +
    </div>
 +
 
 +
<div class="thumb" style="margin-top:15px;margin-bottom:15px;">
 +
  <div class="thumbinner" style="width:450px;"><img alt="Fluorescence Readout" src="https://static.igem.wiki/teams/5237/wetlab-results/catb-results/catb-fluorescence-readout-null-negative-test-w.svg" width="450"
 +
            class="thumbimage">
 +
        <div class="thumbcaption">
 +
          <i><b>Figure 8: Fluorescence Readout After 48&nbsp;Hours for Two Control Conditions and One Test Condition.</b></i> The fluorescence intensity for mCherry was measured for the GFLG linker and normalized against a baseline eGFP fluorescence intensity. The null control and the negative control were not transfected with the plasmid encoding cathepsin B. The null control was also not transfected with any of the plasmids encoding Gal4-Linker-VP64 constructs. The test sample was transfected with 30&nbsp;ng of the plasmid encoding cathepsin B and with the plasmid encoding Gal4-GFLG-VP64.
 +
        </div>
 +
      </div>
 +
    </div>
 +
</section>
 +
 
 +
<section id="4.3">
 +
<h3>4.3 Mature Cathepsin B Is Expressed in HEK293T Cells</h3>
 +
<p><b>Figure 9</b> shows a western blot of the wild-type (wt) version of cathepsin B as well as the truncated and mutated version of cathepsin B (&Delta;1-20, D22A, H110A, R116A). Cells of both cathepsin B versions were treated with 500 nM doxorubicin (dox) 24&nbsp;hours post-transfection and incubated for additional 24&nbsp;hours. For each condition, three replicates were blotted. We observed no differences in protein expression levels between the dox-treated and untreated wt versions of cathepsin B. For the truncated and mutated version of cathepsin B, however, only the untreated samples showed the corresponding band at approximately 36&nbsp;kDa expected for this version of cathepsin B. Additionally, the bands of the truncated and mutated version appeared much weaker than the ones of the wt, indicating poorer protein expression. The household protein &beta;-tubulin is visible in all samples at approximately 55&nbsp;kDa. The wt cathepsin B additionally showed bands for pro-cathepsin B at approximately 42&nbsp;kDa, a mature single-chain version of cathepsin B at approximately 33&nbsp;kDa and a mature double-chain version at approximately 26&nbsp;kDa.</p>
 +
 
 +
<div class="thumb" style="margin-top:15px;margin-bottom:15px;">
 +
  <div class="thumbinner" style="width:600px"><img alt="Fluorescence Readout" src="https://static.igem.wiki/teams/5237/wetlab-results/catb-wb-w.svg" width="600"
 +
            class="thumbimage">
 +
        <div class="thumbcaption">
 +
          <i><b>Figure 9: Western Blot of Two Versions of Cathepsin B With and Without Doxorubicin.</b></i> From left to right: protein ladder, wild-type (wt) cathepsin B with (+) and without (-) doxorubicin, truncated and mutated version of cathepsin B with (+) and without (-) doxorubicin. The household protein &beta;-tubulin is visible in all samples at 55&nbsp;kDa. The wt cathepsin B also shows bands for pro-cathepsin B at 42&nbsp;kDa, mature single-chain cathepsin B at 33&nbsp;kDa and mature double-chain cathepsin B at 26&nbsp;kDa. The band for the truncated and mutated version of cathepsin B can be seen in the samples without doxorubicin at 36&nbsp;kDa.
 +
        </div>
 +
      </div>
 +
    </div>
 +
</section>
 +
</section>
 +
 
 +
<section id="5">
 +
<h1>5. Conclusion</h1>
 +
 
 +
<section id="5.1">
 +
<h3>5.1 GFLG Is a Promising Candidate for Targeted Applications in Environments With Upregulated Cathepsin B Activity</h3>
 +
<p>All in all, these findings demonstrate that our fluorescence-based readout assay reliably detects cathepsin B-mediated cleavage of peptide linkers, with the GFLG linker showing particularly high susceptibility to enzymatic cleavage. This makes GFLG a promising candidate for targeted applications in environments with elevated cathepsin B activity, such as cancerous tissues.<br>
 +
Additionally, our assay can be used to identify other cathepsin B-cleavable peptide linkers or improve our current GFLG linker. Our assay can also be adapted for other proteases, such as different caspases involved in neurodegenerative conditions (Espinosa-Oliva <i>et al.</i>, 2019).</p>
 +
</section>
 +
 
 +
<section id="5.2">
 +
<h3>5.2 Enabling the Functionalization of our PICasSO Toolbox Through Cathepsin B Cleavage</h3>
 +
<p>Our GFLG linker can be combined with caged inteins (Gramespacher <i>et al</i>., 2017) conjugated to catalytically dead Cas9, allowing for selective induction of Cas-stapling in the presence of cathepsin B. This enables the functionalization of our PICasSO toolbox for <i>in vitro</i> and <i>in vivo</i> applications.<br>
 +
This innovative approach paves the way for new strategies in precision medicine and synthetic biology, offering the potential for targeted therapeutic interventions.</p>
 +
</section>
 +
 
 +
</section>
 +
 
 +
   <section id="6">
 +
     <h1>6. References</h1>
 
     <p>
 
     <p>
 
Bien, S., Ritter, C. A., Gratz, M., Sperker, B., Sonnemann, J., Beck, J. F., Kroemer, H. K. (2004). Nuclear factor-kappaB mediates up-regulation of cathepsin B by doxorubicin in tumor cells. Molecular Pharmacology 65(5), 1092-102. <a
 
Bien, S., Ritter, C. A., Gratz, M., Sperker, B., Sonnemann, J., Beck, J. F., Kroemer, H. K. (2004). Nuclear factor-kappaB mediates up-regulation of cathepsin B by doxorubicin in tumor cells. Molecular Pharmacology 65(5), 1092-102. <a
Line 333: Line 469:
 
</p>
 
</p>
 
<p>
 
<p>
Gramespacher, J. A., Stevens, A. J., Nguyen, D. P., Chin, J. W., & Muir, T. W. (2017). Intein Zymogens: Conditional Assembly and Splicing of Split Inteins via Targeted Proteolysis. J Am Chem Soc, 139(24), 8074-8077. <a
+
Espinosa-Oliva, A. M., García-Revilla, J., Alonso-Bellido, I. M., & Burguillos, M. A. (2019). Brainiac Caspases: Beyond the Wall of Apoptosis [Mini Review]. Frontiers in Cellular Neuroscience, 13. <a
 +
        href="https://doi.org/10.3389/fncel.2019.00500" target="_blank">https://doi.org/10.3389/fncel.2019.00500</a>
 +
</p>
 +
<p>
 +
Gramespacher, J. A., Stevens, A. J.,&nbsp;Nguyen, D. P., Chin, J. W., & Muir, T. W. (2017). Intein Zymogens: Conditional Assembly and Splicing of Split Inteins via Targeted Proteolysis. J Am Chem Soc, 139(24), 8074-8077. <a
 
         href="https://doi.org/10.1021/jacs.7b02618" target="_blank">https://doi.org/10.1021/jacs.7b02618</a>  
 
         href="https://doi.org/10.1021/jacs.7b02618" target="_blank">https://doi.org/10.1021/jacs.7b02618</a>  
 
</p>  
 
</p>  

Latest revision as of 13:56, 30 September 2024


BBa_K5237010

Cathepsin B-Cleavable Linker: GFLG

This basic part encodes the GFLG peptide linker, a cathepsin B-responsive cleavage site, which can be used for targeted drug delivery or diagnostics in cancerous tissues. As a part of our PICasSO toolbox, the GFLG linker can facilitate precise control of protein activity through cleavage-induced oligomerization of catalytically dead Cas proteins. Through fluorescence readout assays, we verified that the overexpression of cathepsin B in cancer cells can potentially be leveraged for novel therapeutic and biotechnological applications.
We overexpressed cathepsin B in HEK293T cells to investigate the cleavage of five different peptide linkers using our mCherry Expression Cassette (BBa_K5237022). To validate the functionality of the GFLG linker, we cloned it into a mammalian expression vector in between the Gal4 and VP64 domains (BBa_K5237020). Functional testing of this fusion protein demonstrated efficient cleavage by cathepsin B in vivo when cells were treated with doxorubicin, while other tested linkers showed no significant response.

 

The PICasSO Toolbox


Figure 1: Example how the part collection can be used to engineer new staples


The 3D organization of the genome plays a crucial role in regulating gene expression in eukaryotic cells, impacting cellular behavior, evolution, and disease. Beyond the linear DNA sequence, the spatial arrangement of chromatin, influenced by DNA-DNA interactions, shapes pathways of gene regulation. However, the tools to precisely manipulate this genomic architecture remain limited, rendering it challenging to explore the full potential of the 3D genome in synthetic biology. We - iGEM Team Heidelberg 2024 - have developed PICasSO, a powerful molecular toolbox based on various DNA-binding proteins to address this issue.

The PICasSO part collection offers a comprehensive, modular platform for precise manipulation and re-programming of DNA-DNA interactions using protein staples in living cells, enabling researchers to recreate natural 3D genomic interactions, such as enhancer hijacking, or to design entirely new spatial architectures for gene regulation. Beyond its versatility, PICasSO includes robust assay systems to support the engineering, optimization, and testing of new staples, ensuring functionality in vitro and in vivo. We took special care to include parts crucial for testing every step of the cycle (design, build, test, learn) when engineering new parts

At its heart, the PICasSO part collection consists of three categories.
(i) Our DNA-binding proteins include our finalized enhancer hijacking Cas staple as well as half staples that can be used by scientists to compose entirely new Cas staples in the future. We also include our simple staples that serve as controls for successful stapling and can be further engineered to create alternative, simpler and more compact staples.
(ii) As functional elements, we list additional parts that enhance the functionality of our Cas and Basic staples. These consist of protease-cleavable peptide linkers and inteins that allow condition-specific, dynamic stapling in vivo. Besides staple functionality, we also include the parts to enable the efficient delivery of PICasSO's constructs with our interkingdom conjugation system.
(iii) As the final component of our collection, we provide parts that support the use of our custom readout systems. These include components of our established FRET-based proximity assay system, enabling users to confirm accurate stapling. Additionally, we offer a complementary, application-oriented testing system for functional readout via a luciferase reporter, which allows for straightforward experimental simulation of enhancer hijacking.

The following table gives a complete overview of all parts in our PICasSO toolbox. The highlighted parts showed exceptional performance as described on our iGEM wiki and can serve as a reference. The other parts in the collection are versatile building blocks designed to provide future iGEMers with the flexibility to engineer their own custom Cas staples, enabling further optimization and innovation.

Our part collection includes:

DNA-binding proteins: The building blocks for engineering of custom staples for DNA-DNA interactions with a modular system ensuring easy assembly.
BBa_K5237000 fgRNA Entryvector MbCas12a-SpCas9 Entryvector for simple fgRNA cloning via SapI
BBa_K5237001 Staple subunit: dMbCas12a-Nucleoplasmin NLS Staple subunit that can be combined to form a functional staple, for example with fgRNA and dCas9
BBa_K5237002 Staple subunit: SV40 NLS-dSpCas9-SV40 NLS Staple subunit that can be combined to form a functional staple, for example with our fgRNA or dCas12a
BBa_K5237003 Cas-Staple: SV40 NLS-dMbCas12a-dSpCas9-Nucleoplasmin NLS Functional Cas staple that can be combined with sgRNA or fgRNA to bring two DNA strands in close proximity
BBa_K5237004 Staple subunit: Oct1-DBD Staple subunit that can be combined to form a functional staple, for example with TetR.
Can also be combined with a fluorescent protein as part of the FRET proximity assay
BBa_K5237005 Staple subunit: TetR Staple subunit that can be combined to form a functional staple, for example with Oct1.
Can also be combined with a fluorescent protein as part of the FRET proximity assay
BBa_K5237006 Simple taple: TetR-Oct1 Functional staple that can be used to bring two DNA strands in close proximity
BBa_K5237007 Staple subunit: GCN4 Staple subunit that can be combined to form a functional staple, for example with rGCN4
BBa_K5237008 Staple subunit: rGCN4 Staple subunit that can be combined to form a functional staple, for example with rGCN4
BBa_K5237009 Mini staple: bGCN4 Assembled staple with minimal size that can be further engineered
Functional elements: Protease cleavable peptide linkers and inteins are used to control and modify staples for further optimization for custom applications.
BBa_K5237010 Cathepsin B-Cleavable Linker (GFLG) Cathepsin B cleavable peptide linker, that can be used to combine two staple subunits, to make responsive staples
BBa_K5237011 Cathepsin B Expression Cassette Cathepsin B which can be selectively express to cut the cleavable linker
BBa_K5237012 Caged NpuN Intein Undergoes protein transsplicing after protease activation, can be used to create functionalized staple units
BBa_K5237013 Caged NpuC Intein Undergoes protein transsplicing after protease activation, can be used to create functionalized staple units
BBa_K5237014 fgRNA processing casette Processing casette to produce multiple fgRNAs from one transcript, can be used for multiplexing
BBa_K5237015 Intimin anti-EGFR Nanobody Interkindom conjugation between bacteria and mammalian cells, as alternative delivery tool for large constructs
Readout Systems: FRET and enhancer recruitment to measure proximity of stapled DNA in bacterial and mammalian living cells enabling swift testing and easy development for new systems.
BBa_K5237016 FRET-Donor: mNeonGreen-Oct1 Donor part for the FRET assay binding the Oct1 binding cassette. Can be used to visualize DNA-DNA proximity
BBa_K5237017 FRET-Acceptor: TetR-mScarlet-I Acceptor part for the FRET assay binding the TetR binding cassette. Can be used to visualize DNA-DNA proximity
BBa_K5237018 Oct1 Binding Casette DNA sequence containing 12 Oct1 binding motifs, can be used for different assays such as the FRET proximity assay
BBa_K5237019 TetR Binding Cassette DNA sequence containing 12 Oct1 binding motifs, can be used for different assays such as the FRET proximity assay
BBa_K5237020 Cathepsin B-Cleavable Trans-Activator: NLS-Gal4-GFLG-VP64 Readout system that responds to protease activity. It was used to test Cathepsin-B cleavable linker.
BBa_K5237021 NLS-Gal4-VP64 Trans-activating enhancer, that can be used to simulate enhancer hijacking.
BBa_K5237022 mCherry Expression Cassette: UAS, minimal Promotor, mCherry Readout system for enhancer binding. It was used to test Cathepsin-B cleavable linker.
BBa_K5237023 Oct1 - 5x UAS binding casette Oct1 and UAS binding cassette, that was used for the simulated enhancer hijacking assay.
BBa_K5237024 TRE-minimal promoter- firefly luciferase Contains Firefly luciferase controlled by a minimal promoter. It was used as a luminescence readout for simulated enhancer hijacking.

1. Sequence Overview

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

2. Usage and Biology

Cathepsin B is a cysteine protease that is significantly overexpressed in various cancer types, including breast and colorectal cancer (Ruan et al., 2015). Proteolytic cleavage of pro-biologics, for example through cathepsin B activity, allows for precise temporal and spatial regulation of biopharmaceutical activity in therapeutic strategies (Bleuez et al., 2022).
In this context, we introduce the cathepsin B-cleavable peptide linker GFLG as a functional addition to our PICasSO toolbox, enabling a wide range of therapeutic and synthetic biology applications. GFLG has been shown to be cleaved by cathepsin B (Wang et al., 2024), with cleavage occurring either between the phenylalanine and leucine or after the second glycine of the linker (Rejmanová et al., 1983; see Fig. 2).
Through a fluorescence readout assay in HEK293T cells, we identified GFLG as the most effective among five peptide linkers known to be cleaved by cathepsin B (Jin et al., 2022; Shim et al., 2022; Wang et al., 2024). This linker could facilitate cleavage-induced oligomerization of Cas proteins via protein trans-splicing of caged intein fragments (BBa_K5237012, BBa_K5237013), further enhancing the capabilities of our system.

GFLG Peptide Linker Cleavage
Figure 2: Cathepsin B Cleavage Sites in the GFLG Peptide Linker.

3. Assembly and Part Evolution

3.1 Implementation of a Cleavage-Responsive Fluorescence Readout Assay

We designed a fluorescence readout assay in HEK293T cells based on expression of mCherry induced by the trans-activator VP64. VP64 was conjugated to the DNA-binding domain (DBD) of Gal4 through the GFLG linker. We purchased the nucleotide sequence encoding the GFLG linker as an oligo. After annealing the oligo, we cloned it into a mammalian expression vector between the open reading frames for Gal4-DBD and VP64 via Golden Gate assembly (BBa_K5237020). Binding of Gal4-DBD upstream of a gene encoding the fluorescence protein mCherry induces overexpression of mCherry by VP64. Consequently, separation of Gal4-DBD and VP64 by cathepsin B cleavage of the GFLG linker reduces mCherry expression (see Fig. 3).

Cathepsin B Fluorescence Readout Assay
Figure 3: Schematic Illustration of the Cathepsin B Fluorescence Readout Assay. The DNA-binding domain (DBD) of Gal4 is conjugated to the transactivator domain VP64 via a cathepsin B-cleavable peptide linker. Binding of the Gal4-DBD to the upstream activating sequence (UAS) in proximity to the mCherry gene induces mCherry overexpression via VP64. Cathepsin B cleavage of the linker separates Gal4-DBD and VP64 and consequently reduces mCherry expression.

We transfected our genetic constructs into HEK293T cells. The negative control was not transfected with the plasmid encoding cathepsin B. We investigated two different test conditions, in which we either transfected 30 ng or 60 ng of the plasmid encoding cathepsin B. The fluorescence intensity of mCherry was measured 48 hours after transfection. Our initial tests did not result in the unambiguous identification of a cathepsin B-cleavable peptide linker (see Fig. 4). For all linkers, we did not observe a large decrease in fluorescence intensity between the negative control and test conditions. In some conditions, the fluorescence intensity even increased between the negative control and test conditions.

Fluorescence Readout
Figure 4: Fluorescence Readout After 48 Hours for Five Different Peptide Linkers and Three Different Conditions. The fluorescence intensity for mCherry was measured for five different linkers. The negative control was not transfected with the plasmid encoding cathepsin B. The fluorescence intensity of the negative control was set to one. Two different test conditions were investigated, in which either 30 ng or 60 ng of the plasmid encoding cathepsin B were transfected.

3.2 Changes to the Amino Acid Sequence of Cathepsin B Did Not Improve Cleavage Efficiency

Since cathepsin B is a lysosomal protease that is normally only active in the lysosome and the extracellular environment but not in the cytosol, we decided to change the native amino acid sequence of cathepsin B. Upon further investigation of the lysosomal maturation process of cathepsin B, we chose to express a truncated and mutated version of cathepsin B. We truncated the native cathepsin B amino acid sequence N-terminally by the first twenty amino acids. This N-terminally truncated version of cathepsin B lacks a signal peptide that normally facilitates translation of cathepsin B in the rough endoplasmic reticulum. Additionally, truncation of the first twenty amino acids of cathepsin B had previously been observed to maintain catalytic activity even in the absence of lysosomal proteases like pepsin (Müntener et al., 2005). Additionally, we introduced three point mutations (D22A, H110A, R116A) in the amino acid sequence of cathepsin B. This has been shown to increase the activity of cathepsin B at higher pH values by disrupting the interactions of an occluding loop with the substrate binding pocket of cathepsin B (Nägler et al., 1997).
We performed the same fluorescence readout assay in HEK293T cells that we also used for wild-type cathepsin B. The fluorescence intensity of mCherry was measured 48 hours after transfection. However, we observed no decrease in fluorescence between our negative control and test conditions, indicating that Gal4-DBD-Linker-VP64 was not cleaved (see Fig. 5). Additionally, we performed a western blot, where the bands for the truncated and mutated version of cathepsin B were barely visible or absent altogether, indicating lower protein expression compared to the wild type (see Fig. 9). Another key insight from this experiment was that this version of cathepsin B was not activated by cleavage in the cell, as no additional protein bands were observed.

Fluorescence Readout
Figure 5: Fluorescence Readout for the Truncated and Mutated Version of Cathepsin B. Fluorescence intensity for mCherry was measured across five different linkers. The negative control, which was not transfected with the plasmid encoding cathepsin B, was assigned a fluorescence intensity value of one. Two test conditions were explored, where either 30 ng or 60 ng of the plasmid encoding cathepsin B was transfected.

3.3 Doxorubicin Induces Lysosomal Escape of Cathepsin B

Since our truncated and mutated version of cathepsin B did not seem to be active in the cytosol, we decided to go back to wild-type cathepsin B. Therefore, we focused on improving the activity of wild-type cathepsin B in the cytosol. After consulting the literature, we decided to treat cells with the cytostaticum doxorubicin to induce lysosomal escape of cathepsin B, as had been previously reported (Bien et al., 2004).

4. Results

4.1 The Peptide Linker GFLG Is Cleaved by Cathepsin B in Vivo

We performed a fluorescence readout assay in HEK293T cells to investigate cathepsin B cleavage of different peptide linkers. 24 hours after transfection, we added doxorubicin in a final concentration of 500 nM to the cell supernatant. Figure 6 shows the fluorescence intensity of mCherry for five different peptide linkers (GFLG, FFRG, FRRL, VA, FK). The negative control was not transfected with the plasmid encoding cathepsin B. We investigated two different test conditions, in which we either transfected 30 ng or 60 ng of the plasmid encoding cathepsin B. The fluorescence intensity of mCherry was normalized by the measured fluorescence intensity of eGFP in each condition. Additionally, the values for 30 ng and 60 ng cathepsin B were normalized against the corresponding negative controls. One data point for the VA linker, transfected with 60 ng of the plasmid encoding cathepsin B, was excluded due to severe deviation from the other values. We conducted a two-way analysis of variance (ANOVA) to assess the significance of the observed differences between the negative control and the test conditions for each linker. As the negative control did not contain the plasmid encoding cathepsin B, we expected the measured fluorescence intensity of mCherry to be the highest in these conditions. However, this was only observed for the GFLG and FK linkers. Contrary to our expectations, the fluorescence intensity of the negative control was the lowest out of the three conditions tested for the remaining linkers. It appears that the addition of the plasmid encoding cathepsin B increases mCherry fluorescence intensity when the linker is not cleaved. However, this increase is only significant for the FFRG linker in the 60 ng condition. For the GFLG linker, we observed significant decreases in fluorescence intensity between the negative control and both test conditions, with no difference between the 30 ng and 60 ng conditions. For the FK linker, no significant decreases in fluorescence intensity between the negative control and the test conditions were observed.

Fluorescence Readout
Figure 6: Fluorescence Readout After 48 Hours for Five Different Peptide Linkers and Three Different Conditions. The fluorescence intensity for mCherry was measured for five different linkers and normalized against a baseline eGFP fluorescence intensity. The negative control was not transfected with the plasmid encoding cathepsin B. The fluorescence intensity of the negative control was set to one. Two different test conditions were investigated, in which either 30 ng or 60 ng of the plasmid encoding cathepsin B were transfected. The fluorescence readout was analyzed using a two-way ANOVA. Medium: DMEM (10% FCS). P values: ns, P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.

4.2 mCherry and eGFP Can be Used as a Reporter System to Measure Cleavage Efficiency

Figure 7 shows micrographs taken with a fluorescence microscope of three different conditions: the null control, the negative control and the test sample. Figure 8 shows the corresponding graphs quantifying the fluorescence intensity in the different conditions. All samples were transfected with plasmids encoding eGFP and mCherry. The null control and the negative control were not transfected with the plasmid encoding cathepsin B. The null control was also not transfected with any of the plasmids encoding Gal4-Linker-VP64 constructs. The test sample was transfected with 30 ng of the plasmid encoding cathepsin B and with the plasmid encoding Gal4-GFLG-VP64. As expected, the null control showed no detectable mCherry signal, since no plasmid encoding a Gal4-V64 construct was transfected. Consequently, mCherry overexpression via VP64 could not be induced. However, we observed a high fluorescence intensity for eGFP, indicating that the transfection was successful. The negative control showed strong signals of both mCherry and eGFP. Therefore, it can be assumed that the transfection was successful and that our mCherry readout system is functional. Interestingly, there are some cells which either seem to only express mCherry or eGFP and some cells that show no fluorescence signal. The test sample showed less eGFP and mCherry fluorescence compared to the negative control. We expected to observe reduced fluorescence intensity of mCherry, as the transfected cells would express cathepsin B, which cleaves the linker, thereby decreasing mCherry expression.

Fluorescence Readout
Figure 7: Micrographs of HEK293T Cells in Two Control Conditions and One Test Condition. Micrographs were taken with a fluorescence microscope 48 hours after transfection. An overlay of brightfield, eGFP and mCherry is shown. The null control and the negative control were not transfected with the plasmid encoding cathepsin B. The Null Control was also not transfected with any of the plasmids encoding Gal4-Linker-VP64 constructs. The test sample was transfected with 30 ng of the plasmid encoding cathepsin B and with the plasmid encoding Gal4-GFLG-VP64. The micrograph of the test sample is not from the same biological replicate as the micrographs of the two controls.
Fluorescence Readout
Figure 8: Fluorescence Readout After 48 Hours for Two Control Conditions and One Test Condition. The fluorescence intensity for mCherry was measured for the GFLG linker and normalized against a baseline eGFP fluorescence intensity. The null control and the negative control were not transfected with the plasmid encoding cathepsin B. The null control was also not transfected with any of the plasmids encoding Gal4-Linker-VP64 constructs. The test sample was transfected with 30 ng of the plasmid encoding cathepsin B and with the plasmid encoding Gal4-GFLG-VP64.

4.3 Mature Cathepsin B Is Expressed in HEK293T Cells

Figure 9 shows a western blot of the wild-type (wt) version of cathepsin B as well as the truncated and mutated version of cathepsin B (Δ1-20, D22A, H110A, R116A). Cells of both cathepsin B versions were treated with 500 nM doxorubicin (dox) 24 hours post-transfection and incubated for additional 24 hours. For each condition, three replicates were blotted. We observed no differences in protein expression levels between the dox-treated and untreated wt versions of cathepsin B. For the truncated and mutated version of cathepsin B, however, only the untreated samples showed the corresponding band at approximately 36 kDa expected for this version of cathepsin B. Additionally, the bands of the truncated and mutated version appeared much weaker than the ones of the wt, indicating poorer protein expression. The household protein β-tubulin is visible in all samples at approximately 55 kDa. The wt cathepsin B additionally showed bands for pro-cathepsin B at approximately 42 kDa, a mature single-chain version of cathepsin B at approximately 33 kDa and a mature double-chain version at approximately 26 kDa.

Fluorescence Readout
Figure 9: Western Blot of Two Versions of Cathepsin B With and Without Doxorubicin. From left to right: protein ladder, wild-type (wt) cathepsin B with (+) and without (-) doxorubicin, truncated and mutated version of cathepsin B with (+) and without (-) doxorubicin. The household protein β-tubulin is visible in all samples at 55 kDa. The wt cathepsin B also shows bands for pro-cathepsin B at 42 kDa, mature single-chain cathepsin B at 33 kDa and mature double-chain cathepsin B at 26 kDa. The band for the truncated and mutated version of cathepsin B can be seen in the samples without doxorubicin at 36 kDa.

5. Conclusion

5.1 GFLG Is a Promising Candidate for Targeted Applications in Environments With Upregulated Cathepsin B Activity

All in all, these findings demonstrate that our fluorescence-based readout assay reliably detects cathepsin B-mediated cleavage of peptide linkers, with the GFLG linker showing particularly high susceptibility to enzymatic cleavage. This makes GFLG a promising candidate for targeted applications in environments with elevated cathepsin B activity, such as cancerous tissues.
Additionally, our assay can be used to identify other cathepsin B-cleavable peptide linkers or improve our current GFLG linker. Our assay can also be adapted for other proteases, such as different caspases involved in neurodegenerative conditions (Espinosa-Oliva et al., 2019).

5.2 Enabling the Functionalization of our PICasSO Toolbox Through Cathepsin B Cleavage

Our GFLG linker can be combined with caged inteins (Gramespacher et al., 2017) conjugated to catalytically dead Cas9, allowing for selective induction of Cas-stapling in the presence of cathepsin B. This enables the functionalization of our PICasSO toolbox for in vitro and in vivo applications.
This innovative approach paves the way for new strategies in precision medicine and synthetic biology, offering the potential for targeted therapeutic interventions.

6. References

Bien, S., Ritter, C. A., Gratz, M., Sperker, B., Sonnemann, J., Beck, J. F., Kroemer, H. K. (2004). Nuclear factor-kappaB mediates up-regulation of cathepsin B by doxorubicin in tumor cells. Molecular Pharmacology 65(5), 1092-102. https://doi.org/10.1124/mol.65.5.1092

Bleuez, C., Koch, W. F., Urbach, C., Hollfelder, F., & Jermutus, L. (2022). Exploiting protease activation for therapy. Drug Discov Today, 27(6), 1743-1754. https://doi.org/10.1016/j.drudis.2022.03.011

Espinosa-Oliva, A. M., García-Revilla, J., Alonso-Bellido, I. M., & Burguillos, M. A. (2019). Brainiac Caspases: Beyond the Wall of Apoptosis [Mini Review]. Frontiers in Cellular Neuroscience, 13. https://doi.org/10.3389/fncel.2019.00500

Gramespacher, J. A., Stevens, A. J., Nguyen, D. P., Chin, J. W., & Muir, T. W. (2017). Intein Zymogens: Conditional Assembly and Splicing of Split Inteins via Targeted Proteolysis. J Am Chem Soc, 139(24), 8074-8077. https://doi.org/10.1021/jacs.7b02618

Jin, C., EI-Sagheer, A. H., Li, S., Vallis, K. A., Tan, W., & Brown, T. (2022). Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers. Angewandte Chemie International Edition, 61(13), e202114016. https://doi.org/10.1002/anie.202114016

Müntener, K., Willimann, A., Zwicky, R., Svoboda, B., Mach, L., & Baici, A. (2005). Folding Competence of N-terminally Truncated Forms of Human Procathepsin B*. Journal of Biological Chemistry, 280(12), 11973-11980. https://doi.org/10.1074/jbc.M413052200

Nägler, D. K., Storer, A. C., Portaro, F. C. V., Carmona, E., Juliano, L., & Ménard, R. (1997). Major Increase in Endopeptidase Activity of Human Cathepsin B upon Removal of Occluding Loop Contacts. Biochemistry, 36(41), 12608-12615. https://doi.org/10.1021/bi971264+

Rejmanová, P., Kopeček, J., Pohl, J., Baudyš, M., & Kostka, V. (1983). Polymers containing enzymatically degradable bonds, 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Die Makromolekulare Chemie, 184(10), 2009-2020. https://doi.org/10.1002/macp.1983.021841006

Ruan, H., Hao, S., Young, P., & Zhang, H. (2015). Targeting Cathepsin B for Cancer Therapies. Horiz Cancer Res, 56, 23-40.

Shim, N., Jeon, S. I., Yang, S., Park, J. Y., Jo, M., Kim, J., Choi, J., Yun, W. S., Kim, J., Lee, Y., Shim, M. K., Kim, Y., & Kim, K. (2022). Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy. Biomaterials, 289, 121806. https://doi.org/10.1016/j.biomaterials.2022.121806

Wang, J., Liu, M., Zhang, X., Wang, X., Xiong, M., & Luo, D. (2024). Stimuli-responsive linkers and their application in molecular imaging. Exploration, 4(4), 20230027. https://doi.org/10.1002/EXP.20230027